IL5 and eosinophilic esophagitis: However, our transcriptional comparison of benralizumab-treated patients to controls and remission EoE spotlight a broader type 2 inflammatory milieu beyond IL-5, including likely important roles for IL-4 and IL-13, as blockade of these with dupilumab is the only study to date to show any histologic and symptomatic improvement.7